-
2025-522713-29-00
5
2026-03-12
Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
2025-524691-33-00
9
2026-03-09
High-grade epithelial serous or endometrioid epithelial ovarian cancer
-
2025-521284-12-00
5
2026-03-05
Non-small cell lung cancer
-
2025-521785-10-00
5
2026-03-04
Glioblastoma
-
2025-521035-37-00
5
2026-03-02
Immune system diseases
-
2025-523297-16-00
1
2026-02-27
Non-Hodgkin Lymphoid Malignancies (NHLs)
-
2024-517899-38-00
4
2026-02-25
Clear Cell Renal Cell Carcinoma (ccRCC)
-
2025-522873-12-00
5
2026-02-24
ER+, HER2- Advanced Breast Cancer
-
2025-521124-29-00
10
2026-02-13
Non-Small Cell Lung Cancer
-
2025-521513-14-00
4
2026-02-10
Ovarian Cancer
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2025-521606-18-00
4
2026-01-29
Ovarian Cancer
-
2025-522400-24-00
10
2026-01-27
Metastatic urothelial cancer
-
2024-515658-26-00
5
2026-01-21
Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
-
2024-519829-38-00
5
2026-01-09
Heart failure due to systemic left ventricular systolic dysfunction
-
2024-511437-35-00
10
2026-01-05
Patients aged 18-65 years old with newly diagnosed previously untreate
-
2024-519494-19-00
5
2025-12-22
Nutritional and metabolic diseases
-
2024-520130-29-00
4
2025-12-17
Spinal Muscular Atrophy
-
2025-522860-34-00
5
2025-12-16
Small lymphocytic lymphoma (SLL)
-
2025-523009-14-00
4
2025-12-16
Bronchiectasis with chronic pseudomonas aeruginosa colonization
-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2025-523083-21-00
5
2025-12-08
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
-
2024-517261-16-00
9
2025-12-05
Advanced solid tumors
-
2025-521382-27-00
10
2025-12-04
Moderately to Severely Active Crohn's Disease